Author Archives: Charles Moore

Setback in Regulus Candidate for Alport Syndrome Treatment Expected to Be Temporary

Regulus is leveraging its oligonucleotide drug discovery and expertise to develop innovative medicines that target microRNAs for the treatment of several diseases, including Alport syndrome. MicroRNAs are small non-coding RNA molecules that regulate most genes in plants, animals, and some viruses. According to Regulus, a single microRNA can target and regulate hundreds…

Create your own user feedback survey